Suggested remit - To appraise the clinical and cost effectiveness of durvalumab within its marketing authorisation for untreated metastatic urothelial cancer
Following on from information provided to NICE by the company in June 2020, the appraisal of Durvalumab for untreated metastatic urothelial cancer [ID1169] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1169
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 23 November 2022 | Discontinued. Following on from information provided to NICE by the company in June 2020, the appraisal of Durvalumab for untreated metastatic urothelial cancer [ID1169] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 30 June 2020 | Note added to the project documents |
| 30 June 2020 | Suspended. Topic is suspended |
| 04 April 2019 | Note added to the project documents |
| 19 October 2018 - 16 November 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 13 February 2018 | In progress. Topic referred |
For further information on our processes and methods, please see our CHTE processes and methods manual